Skip to content
Tamsulosin
Flomax, Jalyn (tamsulosin) is a small molecule pharmaceutical. Tamsulosin was first approved as Flomax on 1997-04-15. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1D adrenergic receptor, and alpha-1B adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
Trade Name
FDA
EMA
Flomax (generic drugs available since 2010-03-02)
Combinations
Jalyn (generic drugs available since 2010-03-02)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dutasteride
+
Tamsulosin hydrochloride
Tradename
Company
Number
Date
Products
JALYNWoodward Pharma ServicesN-022460 RX2010-06-14
1 products, RLD, RS
Tamsulosin hydrochloride
Tradename
Company
Number
Date
Products
FLOMAXSanofiN-020579 RX1997-04-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
flomaxNew Drug Application2023-01-04
jalynNew Drug Application2020-12-29
tamsulosin hydrochlorideANDA2023-05-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic hyperplasiaEFO_0000284D011470N40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA02: Tamsulosin
— G04CA52: Tamsulosin and dutasteride
— G04CA53: Tamsulosin and solifenacin
— G04CA54: Tamsulosin and tadalafil
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gaucher diseaseD005776Orphanet_355E75.222153213
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAMSULOSIN
INNtamsulosin
Description
Tamsulosin is a 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide that has (R)-configuration. A specific alpha1 adrenoceptor antagonist used (generally as its hydrochloride salt, tamsulosin hydrochloride) in the treatment of prostatic hyperplasia, chronic prostatitis, urinary retention, and help with the passage of kidney stones. It has a role as an alpha-adrenergic antagonist and an antineoplastic agent. It is a conjugate base of a tamsulosin(1+). It is an enantiomer of an ent-tamsulosin.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Identifiers
PDB—
CAS-ID106133-20-4
RxCUI77492
ChEMBL IDCHEMBL836
ChEBI ID9398
PubChem CID129211
DrugBankDB00706
UNII IDG3P28OML5I (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1D
ADRA1D
ADRA1B
ADRA1B
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
148
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Q9UD67
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,493 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
374 adverse events reported
View more details